Diseases, Conditions, Syndromes

Swiss giant Novartis halts COVID-19 hydroxychloroquine study

Swiss pharmaceuticals giant Novartis has decided to halt a clinical trial of hydroxychloroquine as a treatment for COVID-19, citing problems in recruiting enough patients for the study of the controversial drug.

Diseases, Conditions, Syndromes

Hydroxychloroquine COVID-19 prevention trials incomplete: WHO

Hydroxychloroquine can be ruled out as a treatment for hospitalised COVID-19 patients—but the World Health Organization said Thursday it was aware of ongoing trials into its value as a preventative measure.

Diseases, Conditions, Syndromes

WHO halts hydroxychloroquine trials on COVID-19 patients

The World Health Organization decided Wednesday to halt trials of hydroxychloroquine as a potential treatment for hospitalised COVID-19 patients, finding it did not reduce the mortality rate.

Diseases, Conditions, Syndromes

Hydroxychloroquine ineffective at preventing COVID-19: trial

Taking hydroxychloroquine shortly after being exposed to COVID-19 does not help prevent infection in a statistically meaningful way, scientists reported Wednesday following a clinical trial.

page 4 from 10